MiStent

DEVICE2 trials

Sponsors

ECRI bv, Micell Technologies

Conditions

Coronary Heart DiseaseCoronary Stenosis

Phase 3

Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System)

Micell TechnologiesCoronary Heart Disease

Start: 2015-07-31End: 2022-11-30Updated: 2020-09-04

Unknown Phase

Study Comparing the MiStent SES Versus the XIENCE EES Stent

CompletedNCT02385279

ECRI bvCoronary Stenosis

Start: 2015-03-20End: 2021-02-04Updated: 2023-05-08

Related Papers

A Randomized Controlled Trial of a Biodegradable Polymer, Microcrystalline Sirolimus-Eluting Stent (MiStent) versus Another Biodegradable Polymer Sirolimus-Eluting Stent (TIVOLI): The DESSOLVE-C Trial

Cardiology Discovery2022-12-084 citations

Comparison of Clinically Adjudicated Versus Flow-Based Adjudication of Revascularization Events in Randomized Controlled Trials

Circulation Cardiovascular Quality and Outcomes2021-10-208 citations

Final 3-Year Outcomes of MiStent Biodegradable Polymer Crystalline Sirolimus-Eluting Stent Versus Xience Permanent Polymer Everolimus-Eluting Stent

Circulation Cardiovascular Interventions2020-05-2929 citations

Site vs. core laboratory variability in computed tomographic angiography-derived SYNTAX scores in the SYNTAX III trial

European Heart Journal - Cardiovascular Imaging2020-05-282 citations

Clinical outcomes of bioabsorbable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: two-year follow-up of the DESSOLVE III trial.

2020-02-0713 citations

A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.

2017-12-0566 citations